Negative pressure wound therapy: Data presented by Smith & Nephew Oct. 23 at the Annual Clinical Symposium on Advances in Skin and Wound Care show that gauze-based negative pressure wound therapy significantly reduced wound dimensions in a prospective, multi-center clinical evaluation of 131 non-grafted patients. The weekly reduction rates in wound area, depth and volume were 8.3%, 15.8% and 20.5%, respectively, Smith & Nephew said. There also was a significant reduction in wound exudate levels from baseline to treatment discontinuation, and a significant increase in the percentage area of the wound bed composed of red granulation tissue over the course of treatment. In a subset analysis of 23 patients with split-thickness skin grafts (STSG) treated with NPWT, the average graft "take" was 83%, including an average take of 50% for diabetics and 95% for non-diabetics. Smith & Nephew markets the Renasys line of NPWT devices
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
